| INFLARX N.V. EO 0,12 |
| Niederlande |
| Gesundheit |
| NL0012661870 / A2H7A5 |
| IF0 (Frankfurt) / IFRX (NASDAQ) |
| FRA:IF0, ETR:IF0, IF0:GR, NASDAQ:IFRX |
| - |
| https://www.inflarx.de/ |
|
InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative therapies that target the body's complement system, a critical component of the i..
>Volltext.. |
| 55.63 Mio. EUR |
| 11.53 Mio. EUR |
| - |
| - |
| - |
| - |
| 1 Mio. EUR |
| 6.64 Mio. EUR |
| - |
| 2.34 |
| - |
| - |
| - |
| - |
| - |
| - |
| INFLARX |
| 14.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|